clinical trial · NCT05504083
Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
InventisBio Co., Ltd·phase2·completed·n = 121
HyperuricemiaD-0120Benzbromarone
brief summary
This is a randomized, open-label, parallel-controlled, multicenter clinical trial in primary hyperuricemia patients with or without gout.
started
Sep 28, 2022
primary completion
May 18, 2024
completion
May 18, 2024
last updated
Oct 15, 2024
official title
A Multicenter Randomized and Controlled Phase IIb Study to Evaluate the Efficacy and Safety of D-0120 Tablets in Patients with Primary Hyperuricemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol